(FILE 'HOME' ENTERED AT 12:49:11 ON 23 JAN 2007)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI, MEDLINE, NAPRALERT, NLDB, NUTRACEUT, PASCAL, ...' ENTERED AT 12:49:22 ON 23 JAN 2007

```
L1          333 S 199114-18-6/RN OR 199114-17-5/RN OR 199114-04-0/RN OR 199113-
L2          270 DUP REM L1 (63 DUPLICATES REMOVED)
L3            6 S L2 AND PD<1999
L4            0 S L3 AND (CELLULOSE)
L5            0 S L3 AND (MICROCRYSTALLINE OR MICROCRYSTAL)
L6            0 S L3 AND (STABILITY OR STABLE)
L7            0 S L3 AND AVICEL
L8           52 S MICROCRYSTALLINE (P) (ANTIDIABETIC OR THIAZOLIDINEDIONES)
L9           45 DUP REM L8 (7 DUPLICATES REMOVED)
L10          35 S L9 AND (MICROCRYSTALLINE (W) CELLULOSE)
L11           4 S L10 AND PD<1999
L12           1 S L11 AND (ANHYDROUS OR LACTOSE)
L13           0 S L12 AND (COMPRESSION)
L14           1 S L12 AND (ANHYDROUS OR WATER)

=> s l14 and (magnesium and talc)
L15           0 L14 AND (MAGNESIUM AND TALC)

=> s l14 and (magnesium )
L16           0 L14 AND (MAGNESIUM )
```

L11 ANSWER 1 OF 4 IFIPAT COPYRIGHT 2007 IFI on STN
AN 03661677 IFIPAT;IFIUDB;IFICDB
TI HIGH RELEASE SOLID PREPARATION, PREPARATION AND USE THEREOF; ORAL ADMINISTERING
INF Remon; Jean Paul, Ghent, BE
IN Remon Jean Paul (BE)
PAF Rijksuniversiteit Gent Laboratorium Voor Farmaceutishe, DE
PA Gent, Universiteit BE (48476)
EXNAM Page, Thurman K
EXNAM Sheikh, Humera N
AG Sughrue Mion, PLLC
PI US 6368634 B1 20020409
WO 9423700 19941027
AI US 1996-537793 19960227
WO 1994-BE29 19940421
19960227 PCT 371 date
19960227 PCT 102(e) date
XPD 9 Apr 2019
PRAI BE 1993-407 19930422
FI US 6368634 20020409
DT Utility
FS CHEMICAL
GRANTED
MRN 007885 MFN: 0504
CLMN 38
GI 4 Drawing Sheet(s), 11 Figure(s).
PI US 6368634 B1 20020409
WO 9423700 19941027
ACLM . . . the pellet to gel in water or in gastric medium, said process comprising: mixing together the active agent, the solid **microcrystalline cellulose** particles and the solubilizer as the only solubilizer present, so as to form a liquid solution of the active agent. . .
. . . components which can cause the pellet to gel in water or in gastric medium, said process comprising: mixing together solid **microcrystalline cellulose** particles and the active agent in powder form, mixing the so obtained mixture with the solubilizer, as the only solubilizer. . .
. . . solubilizer as the only solubilizer present for forming a solution in which the active agent is dissolved, and (c) solid **microcrystalline cellulose** particles on which said solution is fixed, said particles containing said solution being agglomerated in an agglomerate which is not. . .
. . . in which the active agent is dissolved in the solubilizer, and (b) a carrier consisting of an agglomeration of solid **microcrystalline cellulose** particles, said liquid solution being fixed on or in the carrier, said method comprising: dissolving the active agent in said solubilizer as the only solubilizer present so as to form said liquid solution; mixing said solid **microcrystalline cellulose** particles with the liquid solution so as to form a composition of solid particles containing said liquid solution; agglomerating the. . .
. . . which the active agent is selected from the group consisting of hydrochlorothiazide, acetazolamide, acetylsalicylic acid, allopurinol, alprenolol, amiloride, antiarrhythmic, antibiotic, **antidiabetic**, antiepileptic, anticoagulants, antimycotic, atenolol, bendroflumethiazide, benzbromarone, benzthiazide, betamethasone, ester thereof, bronchodilator, buphenine, bupranolol, chemotherapeutic, chlordiazepoxide, chloroquine, chlorothiazide, chlorpromazine, chlortalidone, clenbuterol,. . .
38. Mixture of claim 21, in which the particles are selected from the group consisting of **microcrystalline** particles and water

insoluble particles.

L11 ANSWER 2 OF 4 IFIPAT COPYRIGHT 2007 IFI on STN
AN 02781369 IFIPAT;IFIUDB;IFICDB
TI REDISPERSIBLE NANOPARTICULATE FILM MATRICES WITH PROTECTIVE OVERCOATS; LOW SOLUBILITY DRUGS WITH HIGH BIOAVAILABILITY, STERIC STABILIZER
INF Desieno, Mark A, Gilbertsville, PA
Stetsko, Gregg, Harleysville, PA
IN Desieno Mark A; Stetsko Gregg
PAF Nano Systems LLC, Collegeville, PA
PA NanoSystems LLC (38571)
EXNAM Page, Thurman K
EXNAM Benston, Jr, William E
AG Rudman & Balogh
PI US 5573783 A 19961112 (CITED IN 010 LATER PATENTS)
AI US 1995-387651 19950213
XPD 13 Feb 2015
FI US 5573783 19961112
DT Utility
FS CHEMICAL
GRANTED
MRN 007359 MFN: 0154
007817 0273
007820 0153
007987 0025
CLMN 28
PI US 5573783 A 19961112 (CITED IN 010 LATER PATENTS)
ACLM . . . 2 wherein the drug is selected from the group consisting of analgesics, anti-inflammatory agents, anthelminitics, anti-arrhythmic agents, antibiotics, anticoagulant, antidepressants, **antidiabetic** agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives, astringents, beta-adrenoceptor. . .
. . . 14. The composition of claim 1 wherein the carrier particle is selected from the group consisting of sugar spheres, maltodextrin, **microcrystalline cellulose**, microcrystal cellulose/sodium carboxylmethylcellulose, granular dextrose, dicalcium phosphate, tricalcium phosphate, mono and disaccharides.
. . . 17 wherein the drug is selected from the group consisting of analgesics, anti-inflammatory agents, anthelminitics, anti-arrhythmic agents, antibiotics, anticoagulant, antidepressants, **antidiabetic** agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives, astringents, beta-adrenoceptor. . .

L11 ANSWER 3 OF 4 IFIPAT COPYRIGHT 2007 IFI on STN
AN 01988916 IFIPAT;IFIUDB;IFICDB
TI ORAL ANTI-DIABETIC PHARMACEUTICAL COMPOSITIONS AND THE PREPARATION THEREOF; ACID, BASIC OR AMPHOTERIC BENZOIC ACID DERIVATIVES WITH EXCIPIENTS, SOLVENTS, SOLUBILIZERS, CARRIERS
INF Brickl, Rolf, Warthausen, DE
Greischel, Andreas, Biberach, DE
Rupprecht, Eckhard, Aulendorf-Tannhausen, DE
Schepky, Gottfried, Biberach, DE
IN BRICKL ROLF (DE); GREISCHEL ANDREAS (DE); RUPPRECHT ECKHARD (DE); SCHEPKY GOTTFRIED (DE)
PAF Dr Karl Thomae GmbH, Biberach an der Riss, DE
PA THOMAE, DR KARL GMBH DE (84368)
EXNAM Rollins, John W
AG Felfe & Lynch
PI US 4873080 A 19891010 (CITED IN 004 LATER PATENTS)

AI US 1987-103524 19870930
XPD 10 Oct 2006
RLI US 1984-616010 19840531 CONTINUATION-IN-PART 4708868
PRAI DE 1983-3320583 19830608
FI US 4873080 19891010
US 4708868
DT Utility
FS CHEMICAL
GRANTED
OS CA 112:223301
MRN 005115 MFN: 0672
CLMN 14
GI 16 Drawing Sheet(s), 16 Figure(s).
PI US 4873080 A 19891010 (CITED IN 004 LATER PATENTS)
ACLM . . . claim 1, wherein the dry treated water-insoluble carrier is combined with a conventional pharmaceutical excipient to produce the desired oral **antidiabetic** pharmaceutical composition.
. . . The method of claim 1, wherein the water-insoluble carrier is selected from the group consisting of highly dispersed silicon dioxide, **microcrystalline cellulose**, basic aluminum oxide, magnesium-aluminum-trisilicate, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, tricalcium phosphate, calcium biphosphate and mixtures thereof, and the solubilizing or. . .
9. An oral **antidiabetic** pharmaceutical composition consisting essentially of a conventional pharmaceutical excipient and a dry water-insoluble carrier having applied to the surface thereof the evaporation residue of a solution or emulsion of an effective **antidiabetic** amount of an acid, amphoteric or basic **antidiabetic** benzoic acid, a basic or acid excipient, and at least one solubilizing or emulsifying substance in an inert polar solvent,. . .
. . . is sulfuric acid or tartaric acid, the water-insoluble carrier is selected from the group consisting of highly dispersed silicon dioxide, **microcrystalline cellulose**, basic aluminum oxide, magnesium-aluminum-trisilicate, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, tricalcium phosphate, calcium biphosphate and mixtures thereof, and the solubilitizing or. . .

L11 ANSWER 4 OF 4 IFIPAT COPYRIGHT 2007 IFI on STN
AN 01812788 IFIPAT;IFIUDB;IFICDB
TI ORAL ANTI-DIABETIC PHARMACEUTICAL FORMS AND THE PREPARATION THEREOF
INF Brickl, Rolf, Warthausen, DE
Greischel, Andreas, Biberach, DE
Rupprecht, Eckhard, Aulendorf-Tannhausen, DE
Schepky, Gottfried, Biberach, DE
IN BRICKL ROLF (DE); GREISCHEL ANDREAS (DE); RUPPRECHT ECKHARD (DE); SCHEPKY GOTTFRIED (DE)
PAF Dr Karl Thomae GmbH, Biberach an der Riss, DE
PA THOMAE, DR KARL GMBH DE (84368)
EXNAM Brown, J R
EXNAM Rollins, John W
AG Weissenberger, Hammond & Littell
PI US 4708868 A 19871124 (CITED IN 019 LATER PATENTS)
AI US 1984-616010 19840531
XPD 24 Nov 2004
PRAI DE 1983-3320583 19830608
FI US 4708868 19871124
DT Utility
FS CHEMICAL
GRANTED
MRN 004760 MFN: 0524
CLMN 16
GI 10 Drawing Sheet(s), 10 Figure(s).

PI US 4708868 A 19871124 (CITED IN 019 LATER PATENTS)

ACLM . . . The method of claim 1, wherein the water-insoluble carrier is selected from the group consisting of highly dispersed silicon dioxide, **microcrystalline cellulose**, basic aluminum oxide, magnesium-aluminum-trisilicate, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, tricalcium phosphate, calcium biphosphate and mixtures thereof, and the solubilizing or. . .

. . . claim 1, wherein the dry treated water-insoluble carrier is combined with a conventional pharmaceutical excipient to produce the desired oral **antidiabetic** pharmaceutical composition.

10. An oral **antidiabetic** pharmaceutical composition consisting essentially of a conventional pharmaceutical excipient and a dry water-insoluble carrier having applied to the surface thereof the evaporation residue of a solution or emulsion of an effective **antidiabetic** amount of an acid, amphoteric or basic **antidiabetic** sulfonyl urea, a basic or acid excipient, and at least one solubilizing or emulsifying substance in an inert polar solvent,. . .

. . . the acid excipient is sulfuric acid, the water-insoluble carrier is selected from the group consisting of highly dispersed silicon dioxide, **microcrystalline cellulose**, basic aluminum oxide, magnesium-aluminum-trisilicate, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, tricalcium phosphate, calcium biphosphate and mixtures thereof, and the solubilizing or. . .